After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...

For the first time in 20 years, the Food and Drug Administration has approved a new pharmaceutical approach to treating pain. On January 31, the FDA approved Journavx as ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

By Rick Winterson  Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge.  It has now established its global headquarters on Fan Pier in South ...

The US Food and Drug Administration (FDA) has approved a non-opioid drug for severe post-surgical pain, which could “redefine ...